Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
No human clinical trials have been published to date
A deficiency in B12 can disrupt this process, leading to anemia, impaired red blood cell production and even nerve damage[7]
These integrative and multidimensional interactions shape the system's behavior and must be considered comprehensively over time, space, and the context of appearance (177, 178)
Sermorelin often pairs with GHRPs or other secretagogues in sophisticated protocols designed by experienced researchers
Even at room temperature, these powdered peptides remain stable for several weeks
